Winship's Division Director of Gynecologic Oncology, Dr. Gordon is involved in research and development of chemotherapy combinations for cancer patients.
Titles and Roles
- Director, Division of Gynecologic Oncology
- Winship Cancer Institute
- Professor, Department of Gynecology and Obstetrics
- Emory University School of Medicine
- Research Program
- Discovery and Developmental Therapeutics
Alan N. Gordon, MD, has been board certified in both obstetrics and gynecology since 1985. He specializes in gynecologic oncology and is the Division Director of Gynecologic Oncology at Emory.
Dr. Gordon is a member of the Discovery and Developmental Therapeutics research program at Winship Cancer Institute. He is also a member of the American College of Obstetricians and Gynecologists, the Society of Gynecologic Oncologists, the Felix Rutlege Society, the American Society of Clinical Oncology, the International Society of Gynecologic Oncology, the European Society of Medical Oncology, the American College of Surgeons, and the Johns Hopkins Medical and Surgical Society.
Dr. Gordon attended medical school at Johns Hopkins University School of Medicine and completed his residency at the Johns Hopkins Hospital. Additionally, he completed a gynecologic oncology fellowship at the MD Anderson Cancer Center in 1983.
Dr. Gordon has been recognized on multiple occasions for his outstanding teaching ability. In 2001, Dr. Gordon received the National Faculty Award from the American College of Obstetrics and Gynecology. For the 2005-2006 cycle, Dr. Gordon was awarded "Outstanding Teacher" by the Department of Obstetrics and Gynecology at Banner Good Samaritan Health Center. In 2015, he was welcomed into Emory's MilliPub Club which honors Emory faculty who have published a paper that has garnered more than 1,000 citations.
Dr. Gordon's major research interest is in the area of clinical drug development. The majority of his work has been in phase II and III trials to evaluate efficacy and safety of new drugs and combinations in gynecologic cancers. He has also been involved in phase I safety trials of chemotherapeutic regimens.